The global spinal muscular atrophy (SMA) treatment market size is expected to reach USD 3.9 billion by 2025, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of 12.9% during the forecast period. Due to the rare nature and complexity of these diseases, scientific knowledge pertaining to them is scarce. However, there are various initiatives undertaken to increase awareness regarding rare diseases and to support SMA communities. This is anticipated to boost market development over the coming years.
Various
SMA communities and companies have collaborated for developing disease
treatment therapy. For example, RG7916, which is an investigational therapy
being developed by Roche in collaboration with SMA Foundation and PTC
Therapeutics. Thus, heavy investments in R&D by major companies are also
projected to contribute to the growth of this market. CureSMA, SMA Foundation,
and SMA Europe are some of the organizations actively supporting R&D
pertaining to SMA.
CureSMA
provided funding to a research project to Biogen and Ionis Pharmaceuticals, Inc.
for developing Spinraza, which received U.S. FDA approval in 2016. This
organization has invested nearly USD 70 million in the research pertaining to
SMA, which also included a planned investment of USD 5 million in the coming
years.
Full Research Report On Spinal Muscular Atrophy Treatment Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/spinal-muscular-atrophy-sma-treatment-market
Further key
findings from the study suggest:
- The global
spinal muscular atrophy treatment market is projected to expand at a CAGR
of 12.9% over the forecast period
- Based on
disease type, type 1 accounted for the largest revenue share owing to the
rising incidence of type 1 SMA
- By treatment,
the drug segment accounted for the largest revenue share in 2017
- North America
will retain its lead as the largest regional market; however, Asia Pacific
is anticipated to register the fastest CAGR over the forecast period
- The market is
presently led by Biogen Inc. Biogen’s Spinraza is the only approved
commercialized treatment for SMA, owing to which market is not
competitive. However, this trend is expected to change after the
commercialization of other treatment therapies post-2020
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/spinal-muscular-atrophy-sma-treatment-market/request/rs1
Grand View Research has
segmented the global spinal muscular atrophy treatment market on the basis of
disease type, treatment, route of administration, and region:
SMA Treatment
Disease Type Outlook (Revenue, USD Million, 2015 - 2025)
- Type 1
- Type 2
- Type 3
- Type 4
SMA Treatment
Outlook (Revenue, USD Million, 2015 - 2025)
- Gene Therapy
- Drug
- Spinraza
- RG6083 (Olesoxime)
- RG7916
SMA Treatment
Route of Administration Outlook (Revenue, USD Million, 2015 - 2025)
- Oral
- Intrathecal
SMA Treatment
Regional Outlook (Revenue, USD Million, 2015 - 2025)
- North America
- The U.S.
- Canada
- Europe
- The U.K.
- Germany
- Asia Pacific
- Japan
- China
- Latin America
- Mexico
- Brazil
- Middle East & Africa
- South Africa
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment